BioActor acquisition brings new product potential for Solabia

The acquisition is hoped to further strengthen Solabia’s position on the nutrition market, with a current portfolio of original active ingredients manufactured for the cosmetics, nutraceutical, pharmaceutical, biotechnology and microbiology industries.

Since its launch in 2011, BioActor has developed eight health ingredients, with associated benefits backed by over 20 clinical studies. Based on the Maastricht Health Campus, the company currently serves 20 countries across the globe.

“We are looking forward to working with BioActor to enhance growth for current product portfolio and accelerate the development of new ingredients​”, comments Jean-Baptiste Dellon, CEO of Solabia.

The future for Solabia​

With Solabia’s existing presence in the nutritional market, such as with Algatech’s microalgae-derived active ingredients, the acquisition creates strong potential for further growth within this range in a highly in-demand market.

The partnership will entail BioActor becoming a centre of innovation and clinical research within Solabia’s nutrition division, providing a combined network and expertise, as well as to access new marketing channels and an expanded customer base.

Regarding the acquisition, Hans van der Saag, founder and CEO of BioActor states: “It marks a significant milestone for the company and the people behind its success, and it is an important step towards realising our mission to bring unique and clinically evaluated health ingredients to consumers worldwide.​

“Together with Solabia, we are poised to extend the BioActor growth story as part of a larger organisation with an extensive global footprint, a shared commitment to innovation, research and development, and an unwavering focus on utilising the benefits of nutrition to elevate the health of all of us.”, ​he adds.

Bioactive demands​

It has been established that nutritional status has a vital role in general health and longevity, protecting and preventing the occurrence of various diseases. 

As consumers become increasingly aware of the health benefits that natural food products can exhibit, there has been a similarly increased demand from the nutraceutical industries for the specific bioactives responsible, says Dellon.

BioActor specialises in the extraction of such compounds from the natural ingredient, utilising methods and facilities which it says preserve quality and bioavailability, plus in-house clinical research backing its products.

“BioActor’s pioneering R&D, impressive clinical research capabilities, market leading product portfolio and established customer base will allow us to further strengthen our position in the nutrition and food supplement markets​”, Dellon emphasises.